These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25091705)

  • 1. Solubility and some crystallization properties of conglomerate forming chiral drug guaifenesin in water.
    Fayzullin RR; Lorenz H; Bredikhina ZA; Bredikhin AA; Seidel-Morgenstern A
    J Pharm Sci; 2014 Oct; 103(10):3176-82. PubMed ID: 25091705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride.
    Wang X; Wang XJ; Ching CB
    Chirality; 2002 May; 14(4):318-24. PubMed ID: 11968072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anion effect on the binary and ternary phase diagrams of chiral medetomidine salts and conglomerate crystal formation.
    Choobdari E; Fakhraian H; Peyrovi MH
    Chirality; 2014 Mar; 26(3):183-8. PubMed ID: 24574075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantiomeric 3-chloromandelic acid system: binary melting point phase diagram, ternary solubility phase diagrams and polymorphism.
    Le Minh T; von Langermann J; Lorenz H; Seidel-Morgenstern A
    J Pharm Sci; 2010 Sep; 99(9):4084-95. PubMed ID: 20575001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid-Phase and Oscillating Solution Crystallization Behavior of (+)- and (-)-N-Methylephedrine.
    Tulashie SK; Polenske D; Seidel-Morgenstern A; Lorenz H
    J Pharm Sci; 2016 Nov; 105(11):3359-3365. PubMed ID: 27659160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of molecular flexibility on double polymorphism, solid solutions and chiral discrimination during crystallization of diprophylline enantiomers.
    Brandel C; Amharar Y; Rollinger JM; Griesser UJ; Cartigny Y; Petit S; Coquerel G
    Mol Pharm; 2013 Oct; 10(10):3850-61. PubMed ID: 23984951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solubility of guaifenesin in the presence of common pharmaceutical additives.
    Mani N; Jun HW; Beach JW; Nerurkar J
    Pharm Dev Technol; 2003; 8(4):385-96. PubMed ID: 14601963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the characterization and crystallization of 4-hydroxy-2-pyrrolidone.
    Wang XJ; Wiehler H; Ching CB
    Chirality; 2004 May; 16(4):220-7. PubMed ID: 15034904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of preferential crystallization to resolve racemic compounds in a hybrid process.
    Lorenz H; Polenske D; Seidel-Morgenstern A
    Chirality; 2006 Nov; 18(10):828-40. PubMed ID: 16917833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of preferential enrichment, an unusual enantiomeric resolution phenomenon caused by polymorphic transition during crystallization of mixed crystals composed of two enantiomers.
    Tamura R; Fujimoto D; Lepp Z; Misaki K; Miura H; Takahashi H; Ushio T; Nakai T; Hirotsu K
    J Am Chem Soc; 2002 Nov; 124(44):13139-53. PubMed ID: 12405843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Drug Dev Ind Pharm; 2010 Feb; 36(2):218-26. PubMed ID: 19877992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enabling Direct Preferential Crystallization in a Stable Racemic Compound System.
    Harfouche LC; Brandel C; Cartigny Y; Ter Horst JH; Coquerel G; Petit S
    Mol Pharm; 2019 Nov; 16(11):4670-4676. PubMed ID: 31545612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the Binary System of Proxyphylline Enantiomers: Structural Resolution and Phase Diagram Determination.
    Pinetre C; Harfouche L; Brandel C; Bendeif EE; Sanselme M; Cartigny Y; Couvrat N; Dupray V
    Mol Pharm; 2024 Feb; 21(2):845-853. PubMed ID: 38134443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical properties, binary and ternary phase diagrams of ketoprofen.
    Hong Lu Y; Bun Ching C
    Chirality; 2004 Oct; 16(8):541-8. PubMed ID: 15290690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a solid solution of enantiomers in a racemate-forming system by seeding.
    Huang J; Chen S; Guzei IA; Yu L
    J Am Chem Soc; 2006 Sep; 128(36):11985-92. PubMed ID: 16953640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the phase diagrams of chiral praziquantel.
    Liu Y; Wang X; Wang JK; Ching CB
    Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films.
    Crowley MM; Fredersdorf A; Schroeder B; Kucera S; Prodduturi S; Repka MA; McGinity JW
    Eur J Pharm Sci; 2004 Aug; 22(5):409-18. PubMed ID: 15265510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of heterogeneous nucleation on the surface crystallization of guaifenesin from melt extrudates containing Eudragit L10055 or Acryl-EZE.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Eur J Pharm Biopharm; 2010 May; 75(1):71-8. PubMed ID: 19995604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel stereoselective high-performance liquid chromatographic method for simultaneous determination of guaifenesin and ketorolac enantiomers in human plasma.
    Maher HM; Al-Taweel SM; Alshehri MM; Alzoman NZ
    Chirality; 2014 Oct; 26(10):629-39. PubMed ID: 25043279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.